Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-045970
Filing Date
2024-11-07
Accepted
2024-11-07 07:07:48
Documents
81
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20240930.htm   iXBRL 10-Q 1128133
2 EX-31.1 vndaex311930202410q.htm EX-31.1 10482
3 EX-31.2 vndaex312930202410q.htm EX-31.2 10106
4 EX-32.1 vndaex321930202410q.htm EX-32.1 6674
  Complete submission text file 0001628280-24-045970.txt   6123323

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20240930.xsd EX-101.SCH 47839
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20240930_cal.xml EX-101.CAL 64038
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20240930_def.xml EX-101.DEF 214017
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20240930_lab.xml EX-101.LAB 564090
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20240930_pre.xml EX-101.PRE 406013
84 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20240930_htm.xml XML 785389
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 241433118
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)